Publications

The Add-Aspirin trial has had a number of publications. Please find below a list of each of these publications and a link to access the journal article.

• 2024: Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-B2 and 8-iso-prostaglandin F2α, levels in human urine samples by validated enzyme immunoassays. Scientific Reports

• 2023: Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. British Journal of Cancer 

• 2019: Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. The Lancet Gastroenterology & Hepatology

• 2017: Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clinical Trials

• 2017: Co-enrolment of Participants into Multiple Cancer Trials: Benefits and Challenges. Clinical Oncology

• 2016: Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? Current Colorectal Cancer Rep

• 2016: ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials

• 2014: Are the benefits of aspirin in colorectal cancer limited to PIK3CA mutated cancers? Annals of Oncology

• 2011: Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? BR J Cancer